Biocon’s biosimilar for treating Covid-19: Patients responded positively, says Kiran Mazumdar-Shaw
Posted by
www.biotecnika.org
The Drug Controller General of India (DGCI) has permitted the
Bengaluru-headquartered drug maker to market Itolizumab (ALZUMab)
injection 25 mg/5 mL solution for emergency use in India for treating
cytokine release syndrome (CRS) in moderate to severe ARDS (acute
respiratory distress syndrome) Covid patients.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocons-biosimilar-for-treating-covid-19-patients-responded-positively-says-kiran-mazumdar-shaw/articleshow/76920970.cms
Subscribe to:
Post Comments (Atom)
Post a Comment